Cormorant Asset Management, LP Portfolio Holdings

Cormorant Asset Management, LP

  • $992 Million
  • Q2 2025

Cormorant Asset Management, LP has filed its 13F form on August 14, 2025 for Q2 2025 where it was disclosed a total value porftolio of $992 Million distributed in 42 stocks.

Among their holdings, we can observe that their the top five positions include companies like: Moon Lake Immunotherapeutics with a value of $401M, Eye Point Pharmaceuticals, Inc. with a value of $78.3M, Bridge Bio Pharma, Inc. with a value of $69.1M, Merus N.V. with a value of $58.9M, and Edgewise Therapeutics, Inc. with a value of $55.7M.

Examining the 13F form we can see an increase of $48.8M in the current position value, from $943M to 992M.

Cormorant Asset Management, LP is based out at Boston, MA

Below you can find more details about Cormorant Asset Management, LP portfolio as well as his latest detailed transactions.

Portfolio value $992 Million
Healthcare: $992 Million

Stock Holdings Table Market Cap. of $200 Billions or more

Stock Market Cap. Holding Value (Reported) # of Shares. Last Trade Trade History

Summary

  • Portfolio
  • No. of Stocks 42
  • Current Value $992 Million
  • Prior Value $943 Million
  • Filing
  • Period Q2 2025
  • Filing Date August 14, 2025
  • Form Type 13F-HR
  • Activity in Q2 2025
  • New Purchases 3 stocks
  • Additional Purchases 4 stocks
  • Sold out of 0 stocks
  • Reduced holdings in 16 stocks
Track This Portfolio

Track Cormorant Asset Management, LP Portfolio

Follow Cormorant Asset Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Cormorant Asset Management, LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email